The Tracking Lung Cancer Evolution through Therapy/Rx (TRACERx) lung study brings together a network of experts from across clinical and scientific disciplines and from research centres and hospitals around the UK.
The 9-year programme is led by Professor Charles Swanton (UCL/Francis Crick) and funded by Cancer Research UK. The project aims to collect comprehensive genomic and clinical data from hundreds of non-small cell lung cancer (NSCLC) patients.
TRACERx is the first study to look at the evolution of cancer in real time and immense detail. Using cutting edge analytical techniques and following patients from diagnosis to either cure or relapse, researchers can investigate the genomic landscape of NSCLC, and how tumours evolve, metastasise and develop resistance.
Today, a collection of the latest findings is published by Nature.
Poster image: Lung cancer cells. Credit: Anne Weston, Francis Crick Institute.